NOVERA COMPOUNDS

Tirzepatide 75mg

Coming soon
Purity Guarantee

Tirzepatide 75mg

Sign in to view pricing and purchase this product.

Log In Sign Up

Coming Soon

This peptide will be available soon.

Quantity Discount (%) Price
1 - 5 — $568.00
6 - 10 0.88 % $563.00
11 - 20 1.76 % $558.00
21+ 2.64 % $553.00

Why choose Novera Compounds peptides

Research-grade Quality

Every compound is manufactured to research-grade standards and intended strictly for laboratory and research use. Consistent quality you can build a reproducible protocol around.

Documented and traceable

  • Batch number on every vial

  • Published Certificates of Analysis

  • Purity verified by third-party testing

Handled and shipped with care

Temperature-sensitive compounds are stored and shipped under controlled conditions, so material arrives in the state your research requires. Expert support on hand at every step.

About the product

Tirzepatide is a laboratory-engineered peptide developed to study dual incretin activity under controlled conditions. Classified as a GLP-1/GIP peptide, it contains a modified amino acid sequence that supports consistency during experimental use. With a molecular weight of approximately 4813.48 g/mol, it is supplied as a purified lyophilized powder in a 75mg vial.

Tirzepatide is being explored in research for its potential influence on coordinated metabolic signaling. Its structure enables researchers to study interactions between endocrine activity and cellular responses within structured laboratory models.

Tirzepatide (75mg) Key Features & Specs

  • Subcategory: Weight Loss & Metabolic Peptides
  • Strength: 75mg
  • CAS: 2023788-19-2
  • Chemical Formula: C₂₂₅H₃₄₈N₄₈O₆₈
  • Molecular Weight:  4813.48 g/mol
  • Peptide Sequence: Tyr-Aib-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Ile-Aib-Leu-Asp-Lys(C20-linker)-Ile-Ala-Gln-Lys-Ala-Phe-Val-Gln-Trp-Leu-Ile-Ala-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-NH₂
  • Synonyms: P1206, LY3298176, tirzepatida, tirzepatidum, OYN3CCI6QE

For laboratory research use only.

Tirzepatide (75mg) Research Uses

Tirzepatide is being studied for its role in metabolic and endocrine-related processes. It has been explored for its potential effects on glucose-related activity, insulin signaling, and overall energy regulation in research settings.

Ongoing studies also focus on how this peptide may influence appetite-related signaling and system-wide metabolic coordination. Researchers aim to better understand how dual-function peptides behave across multiple biological systems.

Tirzepatide (75mg) Insights & Observed Findings

Research findings from Tirzepatide studies are derived from in vitro and preclinical models, where concentration ranges vary by experimental design. Researchers select conditions depending on the biological systems being studied.

Studies have observed patterns in metabolic signaling and coordinated cellular responses under controlled conditions. These findings are limited to laboratory settings and are used to guide further research.

Tirzepatide (75mg) Handling & Storage

  • Store Tirzepatide (75 mg) at –20°C in a controlled laboratory environment, protected from light, heat, and moisture to preserve its structural integrity.
  • After reconstitution, store the solution refrigerated.
  • Handle the reconstituted solution with care to maintain consistency in experimental conditions.
  • Avoid repeated freeze-thaw cycles.

Compliance Notice: This product is intended for laboratory research use only and is not approved for human or veterinary use. It is not intended for diagnostic, therapeutic, or clinical applications. Any reference to biological activity or potential effects is based solely on preclinical or in-vitro findings and should not be interpreted as validated clinical outcomes. Researchers are responsible for ensuring proper handling, storage, and disposal in accordance with institutional, federal, and international guidelines.

References

  1. National Center for Biotechnology Information. PubChem Compound Summary for CID 156588324, Tirzepatide. https://pubchem.ncbi.nlm.nih.gov/compound/156588324
  2. Willard FS, Douros JD, Gabe MB, et al. Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist. JCI Insight. 2020;5(17):e140532. Published 2020 Sep 3. doi:10.1172/jci.insight.140532
  3. Sun B, Willard FS, Feng D, et al. Structural determinants of dual incretin receptor agonism by tirzepatide. Proc Natl Acad Sci U S A. 2022;119(13):e2116506119. doi:10.1073/pnas.2116506119
  4. Coskun T, Sloop KW, Loghin C, et al. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept. Mol Metab. 2018;18:3-14. doi:10.1016/j.molmet.2018.09.009
  5. Chavda VP, Ajabiya J, Teli D, Bojarska J, Apostolopoulos V. Tirzepatide, a New Era of Dual-Targeted Treatment for Diabetes and Obesity: A Mini-Review. Molecules. 2022;27(13):4315. Published 2022 Jul 5. doi:10.3390/molecules27134315